This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

This study has been completed.
Information provided by (Responsible Party):
Beth L. Murphy MD, PhD, Mclean Hospital Identifier:
First received: August 22, 2005
Last updated: March 17, 2017
Last verified: March 2017
The purpose of this study is to determine whether the amino acid taurine has effects on mood stability in bipolar disorder.

Condition Intervention Phase
Bipolar Disorder Mania Bipolar Depression Drug: taurine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Taurine as an Anti-manic Agent: a Double-blind Placebo-controlled Study.

Resource links provided by NLM:

Further study details as provided by Beth L. Murphy MD, PhD, Mclean Hospital:

Primary Outcome Measures:
  • Scores on standardized measures of manic and depressive symptoms (HAM-D, MADRS, YMRS) [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Side-effect ratings, general health ratings (SF36) [ Time Frame: 12 weeks ]
  • Drop-outs due to medication changes [ Time Frame: 12 weeks ]

Enrollment: 60
Study Start Date: April 2005
Study Completion Date: December 2011
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Drug: taurine
taurine 2mg BID po
Active Comparator: 2
Drug: taurine
taurine 2mg BID po

Detailed Description:
Taurine is an amino acid that has some actions similar to mood stabilizers. Taurine is widely sold as a component of over-the-counter mood enhancing agents. However, controlled studies examining the mood effects of taurine are limited. An initial study in this laboratory looked at taurine's mood effects in individuals with bipolar disorder. This follow-up study is designed to further examine taurine's effects on manic symptoms. Subjects in the current follow-up study will add taurine or placebo to their current treatment regimen. Both depressive and manic symptoms will be tracked for three months to determine whether the addition of taurine affects mood symptoms.

Ages Eligible for Study:   18 Years to 68 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

bipolar disorder, type I bipolar disorder, type II mania hypomania mixed manic symptoms

Exclusion Criteria:

significant medical or psychiatric co-morbidity pregnancy or planning pregnancy current substance abuse or dependence

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00217165

United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
Principal Investigator: Beth L Murphy, MD, PhD Mclean Hospital
  More Information

Additional Information:
Responsible Party: Beth L. Murphy MD, PhD, Principal Investigator, Mclean Hospital Identifier: NCT00217165     History of Changes
Other Study ID Numbers: 2004P-002669
Study First Received: August 22, 2005
Last Updated: March 17, 2017

Keywords provided by Beth L. Murphy MD, PhD, Mclean Hospital:

Additional relevant MeSH terms:
Bipolar Disorder
Behavioral Symptoms
Bipolar and Related Disorders
Mental Disorders
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on August 22, 2017